Macrogenics Inc financial data

Symbol
MGNX on Nasdaq
Industry
Pharmaceutical Preparations
Location
9704 Medical Center Drive, Rockville, MD
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 350 % -36.2%
Quick Ratio 2.45 % -5.4%
Debt-to-equity 144 % +36.7%
Return On Equity -89.4 % -377%
Return On Assets -27.5 % -876%
Operating Margin -73.7 % +74.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63.1M shares +1.05%
Common Stock, Shares, Outstanding 62.8M shares +1.21%
Entity Public Float 259M USD
Common Stock, Value, Issued 628K USD +1.13%
Weighted Average Number of Shares Outstanding, Basic 62.6M shares +1.12%
Weighted Average Number of Shares Outstanding, Diluted 62.6M shares +1.12%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 150M USD +155%
Research and Development Expense 177M USD +6.37%
General and Administrative Expense 71M USD +36.1%
Costs and Expenses 261M USD +14.8%
Operating Income (Loss) -111M USD +34.3%
Net Income (Loss) Attributable to Parent -67M USD -639%
Earnings Per Share, Basic -1.07 USD/shares -613%
Earnings Per Share, Diluted -1.07 USD/shares -613%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 183M USD +81.1%
Accounts Receivable, after Allowance for Credit Loss, Current 4.31M USD -58.4%
Inventory, Net 0 USD -100%
Assets, Current 217M USD -13.5%
Property, Plant and Equipment, Net 18.1M USD -17.2%
Operating Lease, Right-of-Use Asset 24.5M USD +2.78%
Other Assets, Noncurrent 1.56M USD +12.3%
Assets 262M USD -12.3%
Accounts Payable, Current 5.01M USD -22.2%
Accrued Liabilities, Current 29.3M USD +21%
Contract with Customer, Liability, Current 23.3M USD +25.4%
Liabilities, Current 55.5M USD -1.03%
Contract with Customer, Liability, Noncurrent 55.5M USD -13.6%
Operating Lease, Liability, Noncurrent 32.6M USD +7.95%
Other Liabilities, Noncurrent 1.97M USD +663%
Liabilities 146M USD -0.14%
Retained Earnings (Accumulated Deficit) -1.17B USD -6.07%
Stockholders' Equity Attributable to Parent 116M USD -24%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 120M USD -38.1%
Liabilities and Equity 262M USD -12.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -45.6M USD -256%
Net Cash Provided by (Used in) Financing Activities 248K USD -99.8%
Net Cash Provided by (Used in) Investing Activities 24.8M USD -11.7%
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -20.6M USD -118%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 183M USD +81.1%
Deferred Tax Assets, Valuation Allowance 401M USD +9.94%
Deferred Tax Assets, Gross 410M USD +9.85%
Operating Lease, Liability 37.5M USD +10.3%
Payments to Acquire Property, Plant, and Equipment 1.46M USD +306%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -67M USD -639%
Lessee, Operating Lease, Liability, to be Paid 70.5M USD +0.29%
Property, Plant and Equipment, Gross 107M USD -3.13%
Operating Lease, Liability, Current 4.86M USD +28.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.51M USD +8.32%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.19M USD +29.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33M USD -9.05%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.26M USD +48.7%
Unrecognized Tax Benefits 9.33M USD +19.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.41M USD +50.5%
Depreciation, Depletion and Amortization 1.84M USD -38.3%
Deferred Tax Assets, Net of Valuation Allowance 8.9M USD +5.93%
Share-based Payment Arrangement, Expense 29.4M USD +60.2%
Interest Expense 1.12M USD -22%